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Background: The prevalence of patients with gastrointestinal stromal tumourgst (GIST) who fail currently available
treatments imatinib and sunitinib (third-line treatment-eligible GIST) is unknown, but is expected to be below an
ultra-orphan disease threshold of 2/100,000 population used in England and Wales. Our study was designed to
estimate the prevalence and absolute number of UK patients with unresectable/metastatic GIST at first-, second- and
eventually third-line treatment.
Methods: Our open population model estimates the probability that the prevalence of UK third-line treatment-eligible
GIST patients will remain under the ultra-orphan disease threshold. Model parameters for incidence, proportion of
unresectable/metastatic disease and survival estimates for GIST patients were obtained from a targeted literature review
and a UK cancer register. The robustness of the results was checked through differing scenarios taking extreme values
of the input parameters.
Results: The base-case scenario estimated a prevalence of third-line treatment-eligible GIST of 1/100,000 and a
prevalence count of 598 with a 99.9% likelihood of being below the ultra-orphan disease threshold. The extreme
scenarios, one-way and probabilistic sensitivity analyses and threshold analysis confirmed the robustness of these results.
Conclusions: The prevalence of third-line treatment-eligible GIST is very low and highly likely below the ultra-orphan
disease threshold.
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Gastrointestinal stromal tumours (GIST) are relatively
rare soft tissue mesenchymal tumours occurring in the
gastrointestinal tract, originating in the interstitial cells
of Cajal involved in the regulation of the digestive sys-
tem [1,2]. Recent estimates of GIST annual incidence
quoted in the United Kingdom (UK) range from 1.32–
1.50 per 100,000 population, although none appear
population-based [3,4], equivalent to approximately
800–900 new cases each year [4]. There have been no
UK prevalence studies of GIST published to date, al-
though reports from western Sweden and Hong Kong* Correspondence: javier.cid@evidera.com
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distribution, and reproduction in any mediumhave estimated prevalence at 12.9 per 100,000 [5] and
13.4–15.6 per 100,000 [6], respectively. Epidemiologic
estimates of GIST in the UK have improved since the
diagnostic coding of GIST was introduced in the third
edition of the International Classification of Disease for
Oncology (ICD-O), in 2000. Studies conducted before
this period used the terms leiomyoma, leiomyosarcoma
or leiomyoblastoma to identify GIST [2], likely resulting
in overestimates. Some GIST have been diagnosed as be-
nign and malignant mesenchymal lesions, tumours of
the autonomic and peripheral nervous systems, or be-
nign and malignant tumours not further classified;
hence, these terms have been used sometimes to identify
patients with a potential GIST diagnosis [5].
Currently only resection, dependent on early stage diag-
nosis, offers a potential cure. The proportion of patientsMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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unresectable disease at diagnosis has been reported in the
United States (US), Canada and other European popula-
tions as varying between 13% and 50% [4,7-15]. The Na-
tional Institute for Health and Care Excellence (NICE)
imatinib appraisal has described the proportion of patients
with metastatic/unresectable GIST as between 10% and
30% [4]. For these patients, two lines of systemic therapy
were introduced: first-line imatinib and second-line suniti-
nib in 2001 and 2006, respectively. Among patients who
experience both imatinib and sunitinib treatment failure
(referred to here as ‘third-line treatment-eligible GIST’),
current treatment options are limited to further imatinib
rechallenge at increased dose, participation in clinical tri-
als or best supportive care [16].
The prevalence of GIST patients eligible for third-line
treatment in the UK is not known, but is expected to be
low and potentially below orphan and ultra-orphan dis-
ease thresholds. In the European Union (EU), an orphan
disease is defined as having a prevalence of less than 50
per 100,000 [17]; in England and Wales, NICE has sug-
gested that conditions with a prevalence of less than 2
per 100,000 population may be considered ultra-orphan
[18]. Given the importance of GIST prevalence on or-
phan or ultra-orphan disease status, our study was de-
signed to estimate the prevalence and absolute number
(i.e., prevalence count) of UK patients with unresectable/
metastatic GIST at first-, second- and eventually third-
line treatment. We developed an open-population model
that estimated the number of subjects at each stage of
treatment based on model parameters for GIST inci-
dence, proportion of unresectable/metastatic GIST and
survival estimates for GIST patients. Data to inform the
model parameters were based on targeted literature re-
view and data from a UK cancer register.
Methods
Data sources
To calculate the incidence of GIST, data were requested
from all 11 cancer registers in the UK. Cancer registers
responded to our query but only one register made data
available: the West Midlands Cancer Intelligence Unit
(WMCIU) from 2007 to 2010, owing to the recent intro-
duction and variability in uptake of the specific ICD-O
diagnostic code for GIST across UK cancer registers
[19]. The WMCIU makes anonymized and aggregated
data publically accessible to researchers for a fee to
cover the expenses associated to data extraction, and ac-
knowledgement of its contribution. The WMCIU age
and gender strata incidence rates were applied to the UK
population age and gender distribution to obtain a 2010
UK standardised incidence rate. The total estimated
UK population in 2010 is 62,262,100 [20]. WMCIU
GIST incidence estimates were consistent with availablepublished literature, therefore supporting the quality of
the data obtained from the registry [3-5,8,11,19,21].
Other model parameters were obtained from a tar-
geted literature review. These included: the proportion
of metastatic or unresectable GIST; post-resection GIST
relapse rates; progression-free survival (PFS) or time to
tumour progression (TTP) on first-line treatment (ima-
tinib); PFS or TTP on second-line treatment (sunitinib)
and overall survival (OS) post-imatinib and -sunitinib
treatment failures. For each of these parameters several
references were screened from the literature. Internal
validity of the specific parameter estimates obtained
from the literature, or the degree to which the cited
studies are free from systematic error, is supported
by the peer review process of such studies and the
consistency of their results, that also supports external
validity or generalizability to the UK. External validity is
also expected since the documented parameter value
ranges were narrow and the parameters’ base-case were
chosen around mid-range values.
Sources of published data used to inform the model
parameters are given in Table 1. While some data
sources provided values in the units required by the
model, others needed transformation. For example, sur-
vival figures in a given treatment state expressed as per-
cent of surviving patients at a specific time (month or
year) after treatment initiation required transformation
into yearly rates before they could be used in the model.
While we focused our literature searches on publications
reporting results among UK patients, we considered it
adequate to include publications from studies in the US,
Canada and other European populations to increase the
robustness of our model. To account for background
mortality we used data from the 2010 UK Life Tables avail-
able through the UK Office for National Statistics [20]
weighted by the West Midlands register GIST patient’s
age distribution (2007–2010) [19] and assumed that within
10-year age bands of patients, the incidence of GIST did
not vary. WMCIU data and literature search strategy are
described in the Additional file 1: Appendices.
Model overview
We constructed a model for calculating the prevalence
of GIST in the UK population (Figure 1) that represents
the flow of patients with GIST from first diagnosis to
death via two possible treatment pathways and four
treatment states.
In the first pathway, the newly diagnosed patients with
resectable GIST have their stromal tumour removed sur-
gically and remain in a recurrence-free state for several
years before some of them relapse. At this point those
who relapse enter a state of non-resectable metastatic
GIST and are assumed to receive successful treatment
with imatinib for approximately two years and, during
Table 1 Model parameters





GIST$ incidence (Γ) in person-years 1.053/100000 (SE = 0.139/100000) 0.52/100000 to 1.50/100000 Gamma [3-5,8,11,19,21,31,32]
Proportion of resectable GIST (p) 0.8 (SE = 0.05) 0.50 – 0.90 Beta [4,9,11-13,15,33]
Post-resection GIST TTT$ (γ2)* 0.0464 (SE = 0.0025) 0.029 – 0.186 Gamma [34-38]
Imatinib-treated GIST TTT (γ3)* 0.351 (SE = 0.103) 0.205 – 0.645 Gamma [14,39-44]
Sunitinib-treated GIST TTT (γ4)* 0.974 (SE = 0.085) 0.533 – 1.435 Gamma [45-48]
Third-line treatment-eligible GIST survival (γ5)* 0.904 (SE = 0.10) 0.439 – 1.066 Gamma [24,25,49-53]
Yearly background mortality 0.0314 (SE = 0.0023) 0.0269 – 0.0359 Gamma [20]
$GIST = gastrointestinal stromal tumour; SE = standard error; SA = sensitivity analysis; PSA = probabilistic sensitivity analysis; TTT = time to transition;
*Yearly rate assuming patients’ survival followed an exponential distribution.
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lowing the failure of imatinib treatment, patients receive
sunitinib in a second progression-free state with dur-
ation of approximately nine months. Finally, patients
enter a third state during which they receive a presumed
third line of treatment. They will eventually exit this
final state as they will die. The model also allows patient
exit through the background mortality in each of the
states.
In the second pathway, patients who are metastatic or


























Figure 1 Model to assess GIST patient prevalence in the UK at differe
to transition; UK = United Kingdom. The model parameters are given in Table
62,262,000. Z2 is the number of patients with non-metastatic GIST who have be
with non-resectable metastatic GIST and who are currently progression free wh
of patients who are progression-free while receiving sunitinib and a third-line t
from the duration of relapse-free survival in this state. γ3 is the annual rate of fa
annual rate of failure calculated from the duration of PFS and TTP on sunitinib.
on a range of investigational third-line treatments or best supportive care. Γ =treatment state joining other patients from the first
treatment pathway. From this point, all patients follow
the same treatment pathway until death. The flow
through the model is governed by difference equations
which calculate the annual number of patients present-
ing with GIST and numbers on each treatment type (see
Additional file 1: Appendices). The model parameters
correspond to rates of progression of patients through
the different treatment states. Rates of progression are
derived from what we called ‘time to transition’ (TTT)
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1. Z1 refers to the total UK population and is fixed in all calculations at
en resected and are currently recurrence free. Z3 is the number of patients
ile receiving treatment with imatinib. Similarly, Z4 and Z5 are the numbers
reatment, respectively. γ2 is the annual rate of relapse which is estimated
ilure calculated from the duration of PFS and TTP on imatinib. γ4 is the
γ5 is the annual probability of failure calculated from the duration of OS
incidence of newly diagnosed GIST. p = proportion.
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period of discontinuation upon treatment failure until the
next treatment line is initiated. TTT was therefore in-
ferred from studies reporting PFS or time to tumour
progression for all states, except for third-line treatment-
eligible GIST for which we used OS.
Model parameters, analysis and sensitivity analysis
The model base-case scenario was defined by base-case
values for each model parameter. All seven parameters
in the model require four values to be specified (Table 1).
The first is a base-case parameter estimate, while the
remaining three (minimum value, maximum value,
standard error) are necessary to express the uncertainty
around the base-case value. Parametric uncertainty ana-
lyses were conducted through one-way and probabilistic
sensitivity analysis (PSA) for the base-case and alterna-
tive scenarios. Univariate or one-way sensitivity analysis
consisted of varying each parameter individually between
its assumed minimum and maximum values, which were
informed by the literature review, while fixing all other
parameters at their base-case estimate. Thus, parameters
which are most influential on model results can be
identified.
The PSA consisted of varying all parameter values
simultaneously by sampling each parameter 5,000 times
from statistical distributions, which are specified by the
mean (base-case parameter estimate) and standard error
of each parameter. The beta distribution is valued
between 0 and 1 and is employed in the model to repre-
sent the proportion of subjects at diagnosis with resect-
able GIST. The gamma distribution is strictly positively
valued and is suited to model event rates, representing
the rates of transition between each of the treatment
states. In Table 1 we specified the preferred source for
the base-case value and its standard error for each
model parameter to obtain base-case estimates and to
perform PSA, which provided credibility intervals for
each model outcome.
Given the importance of the choice of two of the base-
case values on model results, three alternative scenarios
were defined based on higher GIST incidence, higher
survival assumptions for third-line treatment-eligible
GIST and higher for both incidence and third-line
treatment-eligible GIST survival. The three aforemen-
tioned alternative scenarios were chosen by combining
extreme values of the two most influential parameters
from the results of the univariate sensitivity analyses.
We also performed threshold analysis. We explored
what the incidence of GIST and the survival of third-line
treatment-eligible GIST patients (two most influential
parameters) would need to be to reach the 2 per 100,000
population prevalence figure corresponding with NICE
ultra-orphan disease threshold. Threshold analysis wasperformed to address this question for each of the two
parameters, while fixing all other parameter values.
Model outcomes
Model outcomes for each scenario included absolute
number and prevalence per 100,000 population of all
patients with GIST, patients in first-line (receiving ima-
tinib) and second-line (receiving sunitinib) treatment
and third-line treatment-eligible GIST patients who ex-
perienced imatinib and sunitinib treatment failures. Each
outcome was expressed with 95% credibility intervals
whose upper and lower limits were determined by the
2.5% and 97.5% percentiles of the outcomes obtained
from the PSA. The PSA also permitted estimation of the
probability that overall and third-line treatment-eligible
GIST populations met orphan or ultra-orphan disease
thresholds used in the UK.
Results
Scenario analysis
The base-case and alternative scenarios 1, 2 and 3 are
presented in Table 2. Under the assumptions of the
model, the base-case scenario indicates that the preva-
lence of third-line treatment-eligible GIST is estimated
as 1.0 per 100,000 population (95% confidence interval
[CI]; 0.7–1.3), and the probability that this figure will re-
main below 2.0 per 100,000 population is 99.9%. In
addition, the prevalence of the total GIST population is
estimated as 15.0 per 100,000 population (95% CI; 11.2–
19.8). The total number of patients living after suffering
GIST (all stages) is estimated at 9,365 (95% CI; 6,953–
12,325) and with third-line treatment-eligible GIST is 598
(95% CI: 432–804). Our model estimated the absolute num-
ber of patients receiving imatinib as 1,422 (95% CI; 838–
2,368) and receiving sunitinib as 599 (95% CI: 435–789).
By comparison, the first alternative scenario, which as-
sumes a higher yearly incidence of GIST of 1.5 per
100,000 population [4], provides a prevalence estimate
of third-line treatment-eligible GIST eligible patients of
1.4 per 100,000 population (95% CI; 1.1–1.7) with a cor-
responding probability of remaining below the 2.0 per
100,000 population threshold of 99.6%. Figures for the
second alternative scenario, which assumes a longer
third-line treatment-eligible GIST survival of 1.5 years,
are higher than those of the base-case and the first alter-
native scenario with respect to third-line treatment-
eligible GIST prevalence and lower in terms of probabil-
ity of the third-line treatment-eligible GIST prevalence
remaining below 2.0 per 100,000 population (threshold).
The third alternative scenario, which assumes both
higher incidence and longer third-line treatment-eligible
GIST survival, produces a third-line treatment-eligible
GIST prevalence of 2.2 per 100,000 population (95% CI:
1.5–3.2) and a probability of 37.9% that the third-line
Table 2 Scenario results produced by the proposed model, with 95% confidence intervals (CI)
Third-line treatment-eligible
GIST* population prevalence
per 100000 persons (95% CI)
Probability that third-line
treatment-eligible GIST
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Absolute number






GIST survival: 0.77 yrs
0.96 (0.69 – 1.29) 99.9% 598 (432 – 804) 15.04 (11.2 – 19.8) 9365 (6953 – 12325) 1422 (838 – 2368) 599 (435 – 789)
Alternative Scenario 1 GIST
Incidence: 1.5/100000 p-y
Third-line treatment-eligible
GIST survival: 0.77 yrs
1.37 (1.06 – 1.73) 99.6% 851 (662 – 1080) 21.9 (13.9 – 31.7) 13364 (10697 – 16383) 2020 (1,252 – 3,258) 855 (670 – 1067)
Alternative Scenario 2 GIST
Incidence: 1.053/100000 p-y
Third-line treatment-eligible
GIST survival: 1.5 yrs
1.53 (1.00 – 2.29) 90.6% 954 (622 – 1428) 15.6 (11.6 – 20.3) 9699 (7227 – 12633) 1410 (832 – 2338) 602 (437 – 802)
Alternative Scenario 3 GIST
Incidence: 1.5/100000 p-y
Third-line treatment-eligible
GIST survival 1.5 yrs
2.18 (1.50 – 3.18) 37.9% 1357 (933 – 1984) 22.3 (17.7 – 27.4) 13886 (1068 – 17069) 2020 (1259 – 3282) 854 (674 – 1061)
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the threshold.
Univariate sensitivity analysis
Univariate sensitivity analysis performed on the base-
case and alternative scenarios demonstrate that the ini-
tial incidence of GIST and third-line treatment-eligible
GIST survival were most influential on the prevalence of
third-line treatment-eligible GIST, as illustrated in the
tornado diagram (Figure 2). Model parameters associ-
ated with survival on imatinib and sunitinib had the
least influence on prevalence of third-line treatment-
eligible GIST.
Threshold analysis
To better quantify the risk associated with the two most
influential parameters, we determined the threshold inci-
dence and third-line treatment-eligible GIST survival
that would cause the third-line treatment-eligible GIST
prevalence to exceed 2.0 per 100,000, while all other pa-
rameters were fixed at the base-case values. This analysis
showed that the incidence of GIST would need to be 2.2
per 100,000 population or higher for the third-line
treatment-eligible GIST population to exceed the thresh-
old. The third-line treatment-eligible GIST transition
rate would have to be 0.31 or higher, corresponding to a
median survival after imatinib and sunitinib failure of at
least 2.2 years.
Discussion
We employed a modelling approach to estimate the
overall number and prevalence of metastatic/unresect-
able GIST patients in the UK and those who failed on
currently licensed treatments. The model demonstrated
that, under a plausible set of assumptions (base-case sce-
nario) of disease incidence and survival, the prevalence0.0 0.5
Sunitinib treated GIST TTT
Imatinib treated GIST TTT
Yearly background mortality
Proportion of resectable GIST
Post-resection GIST TTT
Third-line treatment GIST survival
GIST incidence
Third-line trea
Figure 2 Tornado diagram: Univariate sensitivity analysis for base-cas
GIST survival). GIST = gastrointestinal stromal tumour; TTT = time to transof third-line treatment-eligible GIST is 1.0 (95% CI; 0.7–
1.3) per 100,000, with a 99.9% likelihood of being below
the 2 per 100,000 population threshold for ultra-orphan
disease status in the UK. As data values reported in pub-
lished studies which informed our model parameters are
subject to great variation, we examined three alternative
sets of assumptions.
When we raised the assumed yearly incidence of GIST
to the highest levels reported in Western countries (1.5
per 100,000 persons), the probability that third-line
treatment-eligible GIST prevalence remained below the
ultra-orphan disease threshold was virtually unchanged
(99.6%). This scenario may be plausible given that esti-
mates of the annual incidence of GIST may rise with im-
proved diagnosis of tumours that are tested for c-KIT.
[22] Because a new effective treatment line would prolong
life in the third-line treatment-eligible GIST and therefore
increase prevalence, it was important to assess the longer
patient survival impact on the third-line treatment-eligible
GIST prevalence. By assuming 1.5 years of survival in the
third-line treatment-eligible GIST state, we estimated a
90.6% probability that its prevalence was below the ultra-
orphan disease threshold. Only when assuming both
higher GIST incidence and longer third-line treatment-
eligible GIST survival we obtained a 37.9% probability of
remaining below the threshold of interest.
Sensitivity analysis showed that initial GIST incidence
and third-line treatment-eligible GIST survival were the
most influential variables on the third-line treatment-
eligible GIST prevalence estimate, while threshold ana-
lysis showed that only under extreme assumptions of
these two parameters (GIST incidence greater than 2.2
per 100,000 population or third-line treatment-eligible
GIST survival greater than 2.2 years) would the number
of third-line treatment-eligible GIST patients surpass the
UK ultra-orphan disease threshold. We did not explore1.0 1.5 2.0
tment GIST prevalence per 100,000 persons
e scenario (low incidence and short third-line treatment-eligible
ition.
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estimates of post-resection GIST TTT, imatinib-treated
GIST TTT, sunitinib-treated GIST TTT and the propor-
tion of resectable GIST did not greatly influence our
study findings.
The model predicted the total number of patients liv-
ing after suffering GIST in the base-case to be 9,365
(95% CI; 6,953–12,325) and the number of GIST pa-
tients taking imatinib as 1,422 (95% CI; 838–2,368) or
sunitinib as 599 (95% CI: 435–789).
The understanding of the aetiology and management
of GIST has evolved since it was first differentiated
among other soft tissue sarcomas and two lines of ther-
apy became available for patients with metastatic or
unresectable tumours. However, for a proportion of pa-
tients, these therapies eventually fail and patients who
exhaust their treatments are left with re-challenging with
higher imatinib dose or best supportive care. Several po-
tential third-line treatment drugs [23-25] could be can-
didates for orphan or ultra-orphan disease treatment
status. Orphan and ultra-orphan disease status have impli-
cations on how public funding supports the provision of
treatments, and the speed of access to new treatments for
suitable patients. There could be a case for potential treat-
ments after imatinib and sunitinib failure given the low
number of patients at third-line treatment-eligible GIST.
The major limitation of the study is the face validity of
the model structure and the structure’s inherent assump-
tions on treatment pathways; however, this study pre-
sents a model, understood as a simplified and imperfect
description of reality, which estimates the number of
subjects at each stage of GIST treatment, based on
model parameters available from the literature. Another
limitation we encountered was that data needed to in-
form the model parameters were sparse or unsuitable,
which has also been reported in economic modelling
studies [26-30]. This limitation is common in modelling
studies since it is not always possible to inform all of the
model parameters, considering that the samples of the
available studies are small [27], the evidence for the model
is obtained from only one study [26] or data are used from
other countries and applied to the country of interest due
to lack of local evidence [29].
Some of the reviewed studies reported on important
prognostic variables (i.e., mitotic count, genetic markers)
that identify heterogeneous subgroups within the GIST
patient population. Our model did not explicitly account
for these subgroups as this would have necessitated
stratum-specific TTT estimates that were mostly un-
available. As a result, we have given preference to publi-
cations with large sample sizes where a pool of GIST
patients with a mix of those variables can occur, that is,
studies with heterogeneous patient populations (i.e., dif-
ferent treatment histories, stages of GIST) and responsecriteria. Nonetheless, sensitivity and scenario analysis
showed that the importance of data uncertainty mat-
tered mainly for initial incidence of GIST and third-line
treatment-eligible GIST survival.
We acknowledge that the model’s structure, where all
patients transition through the treatment states sequen-
tially, and assuming that patients cannot skip a particu-
lar treatment line, can be questioned. Another modelling
study included up to seven plausible treatment pathways
for patients with GIST which also depended on limited
data for the proportions of patients following each path-
way, and required assumptions for death rates and state
transition probabilities [4]. We also assumed GIST as not
curable, so all subjects diagnosed with GIST could not exit
the GIST population. Nevertheless, the post-resection
GIST TTT are widely distributed and a long post-
resection GIST TTT (longer than the life expectancy) can
be assumed as cured GIST. Both of these assumptions are
conservative since patients remain in the model for longer,
therefore, leading to overestimation of GIST-related state
prevalences. Our model did not explicitly include path-
ways for adjuvant and neoadjuvant use of tyrosine kinase
inhibitors. These therapeutic strategies can be considered
a combination of the two proposed model pathways.
Conclusion
Despite the study limitations, there is a very high probabil-
ity of third-line treatment-eligible GIST prevalence being
below 2.0 per 100,000 population in the UK, therefore,
remaining below the ultra-orphan disease threshold. This
is relevant because provision of orphan and ultra-orphan
disease status can affect the speed of access to new treat-
ments for suitable patients.
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